Search Results - Johanna Bendell

  • Showing 1 - 13 results of 13
Refine Results
  1. 1
    402 DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone

    402 DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone... by Johanna Bendell, Lu Gan

    Published 2020-11-01
    Article
    Save to List
    Saved in:
  2. 2
    GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors

    GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors by David G DeNardo, Johanna Bendell, Lei Zhou, Jakob Dupont, Anna Galkin

    Published 2021-08-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial

    Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial by Cláudia S. Ferreira, Galina Babitzki, Irina Klaman, Oliver Krieter, Katharina Lechner, Johanna Bendell, Suzana Vega Harring, Florian Heil

    Published 2023-05-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    495 Trial of SNX281, a systemically delivered small molecule STING agonist, in solid tumors and lymphomas

    495 Trial of SNX281, a systemically delivered small molecule STING agonist, in solid tumors and lymphomas by Judy Wang, Gerald Falchook, Johanna Bendell, Meghana Kulkarni, Melissa Johnson, Salah Nabhan, Peter Sandy, Ololade Dosunmu, Humphrey Gardner

    Published 2021-11-01
    Article
    Save to List
    Saved in:
  5. 5
    482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors

    482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors by Judy Wang, Filip Janku, Manish Sharma, Johanna Bendell, Amit Mahipal, George Dranitsaris, Aleksandra Filipovic, Zev Wainber, Joseph Bolen, Eric Elenko, Christopher Korth

    Published 2021-11-01
    Article
    Save to List
    Saved in:
  6. 6
    489 TWT-101: a phase 1 study of the novel HPK1 inhibitor CFI-402411 in patients with advanced cancer

    489 TWT-101: a phase 1 study of the novel HPK1 inhibitor CFI-402411 in patients with advanced cancer by Judy Wang, Omid Hamid, Siqing Fu, Johanna Bendell, Anna Spreafico, Alexander Spira, Kyriakos Papadopoulos, Brigette Ma, Mark Bray, Graham Fletcher, Glenn Michelson, Emily Roberts-Thomson

    Published 2021-11-01
    Article
    Save to List
    Saved in:
  7. 7
    Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

    Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabi... by Zev A. Wainberg, Kynan Feeney, Myung Ah Lee, Andrés Muñoz, Antonio Cubillo Gracián, Sara Lonardi, Baek-Yeol Ryoo, Annie Hung, Yong Lin, Johanna Bendell, J. Randolph Hecht

    Published 2020-07-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

    A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. by Edward Wolin, Alain Mita, Amit Mahipal, Tim Meyer, Johanna Bendell, John Nemunaitis, Pam N Munster, Luis Paz-Ares, Ellen H Filvaroff, Shaoyi Li, Kristen Hege, Hans de Haan, Monica Mita

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors

    389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumo... by Laura Carter, Andrea Wang-Gillam, Johanna Bendell, Wungki Park, Wells Messersmith, Drew Rasco, Lei Zhou, Jean-Marie Bruey, Beatrice Ferguson, Jakob Dupont, Marya Chaney, Johann De Bono, David Nickle, Anna Galkin

    Published 2020-11-01
    Article
    Save to List
    Saved in:
  10. 10
    CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

    CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study by Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu

    Published 2021-07-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

    Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer by David Fogelman, Antonio Cubillo, Pilar García‐Alfonso, María Luisa Limón Mirón, John Nemunaitis, Daniel Flora, Christophe Borg, Laurent Mineur, Jose M. Vieitez, Allen Cohn, Gene Saylors, Albert Assad, Julie Switzky, Li Zhou, Johanna Bendell

    Published 2018-11-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

    CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study by Hendrik-Tobias Arkenau, Marta Gil-Martin, Fiona Thistlethwaite, Karen A. Autio, Patrick A. Ott, Johanna Bendell, Patricia LoRusso, Valentina Boni, Alexander Spira, Javier Garcia-Corbacho, Mark Stroh, Elisabeth G.E. De Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Manreet Randhawa, Greg Durm, Alison L. Hannah

    Published 2021-07-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

    Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer by Lucia Taraborrelli, Yasin Şenbabaoğlu, Lifen Wang, Junghyun Lim, Kerrigan Blake, Noelyn Kljavin, Sarah Gierke, Alexis Scherl, James Ziai, Erin McNamara, Mark Owyong, Shilpa Rao, Aslihan Karabacak Calviello, Daniel Oreper, Suchit Jhunjhunwala, Guillem Argiles, Johanna Bendell, Tae Won Kim, Fortunato Ciardiello, Matthew J. Wongchenko, Frederic J. de Sauvage, Felipe de Sousa e Melo, Yibing Yan, Nathaniel R. West, Aditya Murthy

    Published 2023-09-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: